SUMMARY In this randomized controlled trial, the value of using occupational health nurses (OHNs) to monitor the care of hypertensive employees at work was compared with regular care (RC) delivered in the community. One year after entry, the blood pressure level, medication history, compliance with treatment, and cost of hypertensive care of the participants were determined by independent evaluators. The reduction in diastolic blood pressure (DBP), the measure of effectiveness, was 10.5 ± 1.1 mm Hg (mean ± SEM) in the OHN group and 7.7 ± 1.1 mm Hg in the RC group, and the proportion under good blood pressure control was 41.8% and 31.0% respectively. These between-group differences were not statistically significant. Although the employees in the OHN group were more medicated and had a lower treatment dropout rate, neither difference was statistically significant. In addition, the proportion of employees who were compliant with prescribed medication was virtually identical in both groups. The cost of the care received by employees in the OHN group of $404.14 for the year was substantially higher than that of $250.15 in the RC group with the difference principally related to the cost of visiting the OHNs and a significant difference in drug cost (p < 0.006). The incremental cost-effectiveness (C/E) ratio of $53.67 per mm Hg DBP reduction per year for onsite blood pressure monitoring was higher than the base C/E ratio of $32.65 per mm Hg for regular care. Our findings indicate that monitoring the blood pressure of hypertensive employees at work is neither clinically effective nor cost-effective. Moreover, there is still a significant gap between the control of blood pressure that is potentially achievable when a systematic aggressive approach to treatment is adopted compared with the usual care being delivered in communities at present. (Hypertension 5: 828-836, 1983) KEY WORDS • cost-benefit analysis • allied health personnel * ambulatory care • industrial medicine • delivery of health care • hypertension • occupational health services • patient acceptance of health care I N recent years, the workplace has become a popular focal point for hypertension control programs. Model programs have shown that hypertension screening, treatment, and follow-up can be successfully and efficiently accomplished at work, and the superiority of some of these programs over conventional care has been documented.
I
N recent years, the workplace has become a popular focal point for hypertension control programs. Model programs have shown that hypertension screening, treatment, and follow-up can be successfully and efficiently accomplished at work, and the superiority of some of these programs over conventional care has been documented. 1 " 4 For example, we found that the provision of care at the worksite by a hospital-based health-care team consisting of two specially trained nurses and a supervising physician was significantly more clinically effective and cost-effective than delivery by community physicians. 3 -
The major advantages of on-site treatment programs include access to a relatively large pool of adult employees in a geographically concentrated area and the convenience to the patients involved. Despite these benefits, this approach has not been widely adopted because of concerns about the duplication of medical services, fragmentation of the health care system, and the extra cost of employing additional health care professionals.
In many industries, occupational health nurses monitor the blood pressure of hypertensive employees at the request of the employees or their physicians. Such casual blood pressure assessments, while perhaps of some value to the patients involved, are seldom systematically linked to the antihypertensive treatment they receive in the community. The worksite hypertension control program reported here combines the advantages of industrial and private medicine by having company nurses refer employees with uncontrolled hypertension to their family doctor and monitor their blood pressure at follow-up assessments while leaving clinical decision-making in the hands of the employees' own physicians. This randomized controlled trial was designed to determine whether structured intervention by occupational health nurses is clinically effective and economically sound. In addition, the study afforded an opportunity to relate the process of care delivered by community physicians to the outcome of that treatment.
Methods

Subject Recruitment and Randomization
Study subjects were recruited in a two-stage hypertension detection program for employees 30 to 69 years of age conducted at 38 business locations in Metropolitan Toronto in 1979. Details of the screening method employed have previously been published. 34 For the purposes of the study, an employee's blood pressure was calculated as the average of the second and third readings on two separate occasions 1 week apart. Employees were considered to be eligible for the study if they: 1) had a diastolic blood pressure (DBP) Ss 105 mm Hg or a DBP 2* 95 mm Hg and were already receiving treatment for hypertension; 2) intended to remain with their current employer for the next year; 3) did not have any other medical condition requiring daily medication; and 4) were not pregnant or planning to become pregnant during the study period. Employees whose family physicians objected to their participation in the study were ineligible.
Consenting employees were stratified according to age, sex, DBP, and previous experience with antihypertensive therapy and then allocated to be followed either by their family doctor alone (Regular Care (RC) group) or by their family doctor plus the occupational health nurse at their place of employment (Occupational Health Nurse (OHN) group). All subjects were advised to consult their family physician for the treatment of their hypertension. Those assigned to the RC group were telephoned twice, if necessary, by the study staff to determine if they had seen their physicians and to encourage those who had not to do so. The occupational health nurses were responsible for ensuring that the members of the OHN group were seen by a physician.
Sample Size Calculation
The sample size was selected to detect a 4.0 mm Hg difference in the change in DBP between the two groups, as it was felt that a smaller difference would be of marginal clinical value. With an a of 0.05 and /3 of 0.2 and assuming a standard deviation of the changes in DBP of 8.75 mm Hg (the pooled standard deviation of our previous study 3 ) and a dropout rate of 12%, we estimated that 194 participants were required for the study.
Duties of the Occupational Health Nurses
A detailed protocol of the monitoring of employees as they passed through the three stages of the process of care of hypertensive patients (i.e., referral to a physician, initiation of appropriate therapy, and long-term maintenance of treatment) was developed and described to each OHN by the research staff. The OHN was instructed to ensure that employees saw their family physician and to assist employees without a physician to obtain one. Employees were to be seen by the OHN approximately monthly if their blood pressure was not controlled and every 2 to 3 months if it was controlled. At each visit the OHN was asked to measure the employee's blood pressure, to question the employee about medication side effects and compliance with physician appointments and therapy, and to communicate the results to the family physician. When an employee admitted to low compliance with medication, the OHN, after prior physician approval, was advised to introduce compliance-improving strategies which consisted initially of asking the individual to record on a pocket calendar the doses of their antihypertensive medication taken and those missed. In more difficult situations, strategies found to be useful in other studies were introduced, 5 including more frequent visits to the OHN, "tailoring" of medication ingestion to daily habits, and training in home blood pressure measurements. When physician appointments were missed, the OHN contacted the physician's office to arrange another appointment.
Year-End Assessment
At the end of the study year, all subjects were assessed by independent observers who were unaware of the study group assignments. The variables assessed included blood pressure, medication history, and medication compliance. First, the subjects were visited at home, at which time their blood pressure was assessed, a questionnaire on the care received during the study year was administered, and a pill count made to assess compliance with medication. Those who had discontinued their medication without the consent of their physician were considered to have a percent compliance of zero. Then two additional blood pressure assessments, 1 week apart, were made at the worksite as soon as possible after the home visit. Three readings were made at each blood pressure assessment, and the second and third readings were used to calculate the mean blood pressure.
Although the original study design called for the blood pressure results of the worksite assessment to be used as the endpoint blood pressure, it was found that both groups experienced a statistically significant fall in DBP between the home visit and worksite assessment, being 2.2 ± 1.0 mm Hg and 2.6 ± 1.1 mm Hg in the OHN and RC groups respectively. It appeared that the home visit and notification of an imminent worksite assessment resulted in a subsequent fall in DBP, perhaps by causing the subjects to become more compliant with antihypertensive therapy. Because of this, it was decided to use the result of the first blood pressure assessment made, whether at home or at work, as the endpoint blood pressure. The home visit blood pressure was therefore used for those subjects who had a home visit (OHN = 83; RC = 79), and the result of the first worksite assessment for those who did not (OHN = 8; RC = 8). Subjects were considered to be under good blood pressure control if their average DBP was less than or equal to 90 mm Hg. Subjects were considered to be compliant if they had taken at least 80% of the medication prescribed.
The need for antihypertensive medication was determined from the medication history and a physician telephone questionnaire. An index of therapeutic vigor, based on our modification of derived common "unit" of antihypertensive equivalence from clinical trial reports, 8 was calculated for those employees for whom antihypertensive drugs were prescribed at the year-end. The calculation of this index is described in table 1. "Vigorous therapy" was defined as being prescribed 3 or more units of vigor, which approximately corresponds to 1.5 steps or more in a steppedcare drug regimen. 7 
Economic Analysis
The cost of the medical care received during the year was divided into health system (or direct) costs and patient (or indirect) costs. Health system costs were those directly attributable to treatment and consisted of the cost of the physicians' services, laboratory tests, the OHNs' services and medications. The patient costs were those resulting from time lost from work or leisure and travel costs, and consisted of the time required for visits to physicians, OHNs and laboratories and the related travel costs. The total index of therapeutic vigor is the sum of the number of vigor units for the individual medications prescribed subject to the following restrictions: 1) The maximal effect for any one drug is 0.5 units for furosemide and 2 units for all other drugs; 2) Within any class, the maximal effect is 2 units; and 3) When only Class V drugs are prescribed, the maximal effect is 0.5 units. HCT = hydrochlorothiazide.
The cost of physicians' services and laboratory tests was borne by the Ontario government's universal health insurance plan (OHIP). At the end of the study, subjects were asked to sign a form requesting OHIP to compile statistics on the hypertension-related services for which OHIP had been billed. This included the cost of these services, the number of physician visits, and the date of the most recent physician visit. Because of OHIP policy, these results were mailed directly to the study subjects who were requested to forward this information to the investigators.
To calculate the cost of medication, subjects were asked to keep the receipts for any hypertension-related medication purchased during the study year, and these were collected at the year-end. Subjects who had not kept all their receipts were asked to estimate the number of times that each type of medication had been purchased and the amount spent on each occasion during the year. Subsequent analysis showed that there was no statistically significant difference between drug costs based on receipts and those estimated by the subjects. A medication cost of zero was assigned to all subjects who stated that no medication had been prescribed for them during the year or whose physician had supplied their medication at no charge.
At each visit to the OHN, a patient encounter form was completed that recorded the amount of time the OHN spent seeing the patient, arranging appointments, contacting the employee's physician, completing paperwork, and the time the study subject spent traveling, waiting, and seeing the OHN. At the end of the year, the cost of the OHN services for each subject was determined by multiplying the total OHN time spent by the nurse's hourly wage. The patient cost for the OHN visits was calculated by multiplying the total patient time by the subject's hourly wage.
Study subjects were given a single visit log to complete on their next visit to a physician and laboratory. On it they were asked to record the traveling and waiting time, the time spent with the physician or having the laboratory tests performed, and the cost of travel. At the year end, the subjects were asked to estimate the time required for a typical visit to the physician and to the laboratory. The total amount of time a subject spent on physician or laboratory visits was calculated as zero if no visits were made; the number of visits multiplied by the time recorded on the single visit log if it was completed; or the number of visits multiplied by the estimated time for a typical visit if no log was completed. The patient cost was then calculated as the product of the total time spent and the subject's hourly wage. The direct cost of travel for the physician and laboratory visits was calculated by multiplying the number of visits by the cost from the visit logs if a log was completed or the number of visits by the average per visit cost if a log was not completed.
Only complete data were used to compare the results for individual cost items between groups. In the calculation of health system, patient, and total costs, group means for individual cost items were substituted for missing values.
The cost-effectiveness (C/E) of a treatment program was calculated as the ratio of the average cost per patient to the average reduction in DBP over 1 year. The incremental C/E ratio was calculated as the ratio of the difference in cost between the two groups to the difference in DBP reduction. No discounting of future costs and effects was employed because of the short duration of the study.
Sensitivity Analysis of Cost Data
The practice of substituting group means for missing values in calculating the total cost assumes that the pattern of missing data is random. To test the consequences of possible deviations from randomness for the C/E analysis, a sensitivity analysis was performed as previously described. 4 For the OHN group, missing data for individual cost items were replaced with the 10th percentile of the nonmissing values for that group. The 10th percentile is that value which is greater than or equal to 10% of the observed values and less than or equal to 90%. Similarly, the 90th percentile was used for the RC group.
Referral Failures and Treatment Dropouts
Employees were considered to be "referral failures" if they had not been seen by their physician during the study year. Those who saw their physician but later dropped out of care (had not seen their physician during the last 6 months of the study) were termed "treatment dropouts." The date of the last visit was determined from the data obtained from OHIP and the physician telephone questionnaire.
Statistical Analysis
Means are presented along their standard error and compared by means of paired and unpaired Student's t tests. Proportions were compared using Yates' chisquare test. The Pearson product-moment correlation coefficient was used to measure the correlation between variables. All tests were nondirectional (i.e., two-tailed) and ap value less than 0.05 was considered to indicate a statistically significant difference. In the economic analysis, because the mean per visit cost was substituted for missing values in the calculation of the direct cost of travel for physician and laboratory visits, the observations were not independent, and it was therefore impossible to calculate the standard error of the mean or to test for a difference between the two groups.
Results
Screening and Subject Recruitment
The hypertension screening clinics held to identify potential study subjects were attended by 9743 employees. The flow of these employees through the screening process is illustrated in figure 1 . Of the 213 employees who met the eligibility criteria for the study, 194 (91%) agreed to participate; of these, 97 employees were randomly allocated to the OHN group and 97 to the RC group. acteristics of the employees in the two groups at entry into the study. No statistically significant difference in blood pressure, age, sex, race, or history of antihypertensive medication was found between the two groups.
Completeness of Year-End Assessment
During the study year, five members of the OHN group and four members of the RC group withdrew from the study because they changed employers or retired. Of the remaining subjects, 88 (95.7%) in the OHN group and 86 (92.5%) in the RC group had a year-end blood pressure assessment and answered the year-end questionnaires. In the OHN group, three (3.3%) had only a blood pressure assessment and one (1.1%) refused to participate in the year-end assessment, while the corresponding numbers in the RC group were one (1.1%) and five (5.4%). In addition, one member (1.1%) of the RC group answered the questionnaires but did not have a blood pressure assessment. It was possible to estimate the compliance with medication for 96% of the members of the OHN group and 91 % of the members of the RC group who were known to have seen their physician and were supposed to be taking medication at the end of the study year.
Blood Pressure Results
The results of the year-end blood pressure assessments are shown in table 3. The falls over the study year in DBP by 10.5 ± 1 . 1 mm Hg in the OHN group and 7.7 ± 1.1 mm Hg in the RC group were both statistically significant. There was, however, no statistically significant difference between the two groups at year-end with respect to DBP, the change in DBP, or the proportion whose blood pressure was controlled.
Referral and Treatment
The flow of the employees in the two groups through the medical care process is illustrated in figure  2 . There was no statistically significant difference in the effectiveness of the referral process, with approximately 6% of each group being referral failures. A larger proportion of the OHN group than the RC group was prescribed medication for their hypertension at some point during the year, with the difference between the two groups approaching statistical significance (p = 0.058). Employees in the OHN group visited the nurse an average of 12.1 ± 1.1 times during the year, spending an average of 2.5 ± 0.2 hours with the nurse.
The number of medications prescribed at the yearend is shown in table 4, and the index of therapeutic vigor in table 5. Although the employees in the OHN group were prescribed more medications and were on more vigorous therapy, neither difference was statistically significant. Values in parentheses are the number and percentage of participants for whom data were available and used in estimating the mean cost. For example, data on drug costs were available for 87 (95%) of the members of the OHN group. Participants who retired or changed their place of employment during the study year have been excluded. *SEM and p cannot be determined because of the manner in which the costs were estimated. 
Discussion
We demonstrated that a cohort of uncontrolled hypertensives, identified at a blood pressure survey in industry, had a significant reduction in their blood pressure 1 year after referral to their own physician for assessment and follow-up care. On the other hand, monitoring employees' blood pressure at regular intervals at work by occupational health nurses was not associated with a statistically significant improvement in blood pressure control, although a trend in that direction was observed (0.05 < p < 0.1). Moreover, monitoring antihypertensive care at work was substantially less effective than treating employees on-site since only 41.8% were under good blood pressure control compared with 60.3% in our earlier worksite treatment program. 3 4 In view of the frequent visits by employees to the nurse and the significant amount of time spent in the monitoring process, it is unlikely that this poorer outcome was due to insufficient contact between the occupational health nurses and patients.
Besides blood pressure, the occupational health nurses did not significantly increase the number of medications prescribed, improve compliance with medication therapy, or reduce the dropout rate from therapy. While it is possible that the similarity of outcomes between the two groups may have been related to some unanticipated and beneficial effect of contact between members of the RC and OHN groups, this is improbable since at any given location only approximately one employee in 150 was involved in the study.
The occupational health nurses did appear to have some impact on care delivered by physicians as witnessed by the better blood pressure control and higher cost of drug therapy in the OHN-monitored group. Their ability to influence physician practice behavior was limited, however. Moreover, because the total cost of treatment was substantially higher in the OHN group and since the degree of improvement was modest, monitoring the blood pressure of hypertensive employees was not cost-effective. In addition, the incremental C/E was almost twice that of regular care alone, indicating that this procedure was not worth the extra cost entailed.
Over the course of the study year, the OHN group spent 73% more than the RC group on antihypertensive drugs. To examine the reason for this larger expenditure, we determined the cost of the drugs actually being consumed at the end of the study year and found that the cost of these medications was 30% higher for the OHN group than the RC group. This estimate was derived by multiplying the cost of medications as set out in the Ontario government's 1983 Drug Benefit Formulary, which lists the maximum costs normally paid for drugs prescribed for those eligible for drug benefits in Ontario by the corresponding medication compliance. Since there was no difference in medication compliance at the year end, this increased cost reflects the increased prescription of drugs for the OHN group (table 4) and, especially, the greater use of Step 2 and 3 drugs which, per unit of vigor, are significantly more expensive than Step 1 drugs. The reason for the remaining difference in the cost of medications purchased over the duration of the study is uncertain, but may be related to a difference in compliance early in the study or a more rapid increase in prescribed vigor of therapy in the OHN group. However, these variables were not measured in this study.
It is apparent that there is still a significant gap between the control of blood pressure that is achievable when a systematic aggressive approach to treatment is adopted compared with usual care being delivered in communities today. In the Hypertension Detection and Follow-Up Program (HDFP) study, for example, the proportion of hypertensives receiving care at special treatment clinics at or below goal blood pressure at Year 5 of 64.9% was significantly better than that of 43.6% for those receiving usual care in the community. 7 Similarly, we found that the provision of care at work gave results in terms of blood pressure control which were almost identical to that observed in the stepped-care treatment group in the HDFP study. 3 ' 4 the difference in outcome between usual care and special treatment clinics is unlikely to be related to improved history taking, physical examination, or laboratory assessment since these aspects of the process of care do not bear a clinically important relationship to the success of blood pressure control. Three factors influencing the outcome of antihypertensive therapy have been identified and include: decision to prescribe antihypertensive drugs, vigor of the regimens prescribed, and compliance with prescribed medication. 8 Because medication had already been prescribed for almost 80% of those participating in the occupational health nurse study, the decision to treat was not an important factor in the poor outcome that was observed. Rather, the other two factors appeared to be the key determinants of outcome.
In our study, 91% of those with uncontrolled hypertension were prescribed less than 3 units of vigor, which is roughly equivalent to less than 1.5 steps in a stepped-care approach to treatment (figure 3). Moreover, over half of the employees whose blood pressure remained uncontrolled at the year end were compliant with the regimens that were prescribed. This failure of community physicians to prescribe efficacious drugs in adequate amounts was also observed in our worksite treatment study. 3 In that study, significantly more worksite-treated than regular-care-treated employees were taking more than one type of antihypertensive medication (40.3% vs 13.3%, p < 0.005). Of those untreated, only 27.2% of the regular care participants were at or below goal blood pressure, compared with 57.6% of the worksite participants (p < 0.001). The employees in the OHN group who saw their physician about their blood pressure did so 7.6 ± 0.7 times during the year, compared with 6.3 ± 0.6 visits per year for the RC group (difference not statistically significant).
Compliance with Treatment
The treatment dropout rate of 4.9% per annum in the OHN group was substantially lower than that of 10.4% in the RC group, although the difference was not statistically significant. The proportion of the employees who were compliant with the medication prescribed for them at the year end was virtually identical in both groups, being 55.4% in the OHN group and 55.7% in the RC group. There was no statistically significant relationship between compliance and blood pressure control in either group. Table 6 shows the cost of the care received by the members of the two groups during the study year along with the number and percent of subjects for whom data were available. The annual health system cost was $229.09 for the OHN group and $148.91 for the RC group, the patient cost $175.05 and $101.24 and the total cost $404.14 and $250.15, respectively. The increased cost of the OHN group was principally due to the cost of visiting the OHNs and a significant difference in the drug cost (p < 0.006).
Economic Analysis
The C/E calculations, for the two treatment approaches are shown in table 7. The C/E of utilizing occupational health nurses to monitor antihypertensive care was less, and the incremental C/E more, than that ofRC.
Individual cost items and C/E ratios for the OHN and RC groups were recalculated for the sensitivity analysis by substituting the 10th and 90th percentiles respectively for missing data (table 8) . When this was done, the estimated C/E of the monitoring of hypertensive employees by OHNs became slightly better than that in the RC group and the incremental C/E less. Step 1 Equivalent
Step 2 Equivalent
Step 3 Equivalent 0 1 2 3 4 5 6
PRESCRIBED VIGOR SCALE methods of improving medication compliance that have been shown to be ineffective in clinical trials. 6 Since compliance with drug therapy and change in diastolic blood pressure are significantly correlated, 8 physicians heed to be instructed in ways to improve compliance with therapy. In summary, substantial improvement in the treatment of hypertension is required to improve blood pressure control at the community level. Outcome of care appears to be critically dependent upon the decision to treat, the application of vigorous treatment, and the detection and correction of poor patient compli- Employees were included only if both compliance data and yearend blood pressure data were available.
ance. Occupational health nurses, by monitoring hypertensive employees at work, cannot significantly influence these physician practice behaviors. If community physicians do not substantially improve blood pressure control in the future, special treatment clinics such as those of worksite treatment programs will continue to be an attractive alternative in the management of hypertensive patients.
